Abstract: Compounds of the formula (I), wherein: —X?Y— is selected from —CR<2>=CR<3>— and —CR<2>?N—; R<1> is selected from H, halo, NRR?, NHC(?O)R, NHC(?O)NRR?, NH2SO2R, and C(?O)NRR?; R<2> and R<3> (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R<4> is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R<5> is selected from R<5?>, halo, NHR<5?>, C(?O)NHR<5?>, OR<5?>, SR<5?>, NHC(?O)R<5?>, NHC(?O)NHR<5?>, NHS(?O)R<5?>, wherein R<5?> is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.